Lazard Asset Management LLC Sells 2,380 Shares of Sotera Health (NASDAQ:SHC)

Lazard Asset Management LLC lowered its holdings in shares of Sotera Health (NASDAQ:SHC) by 26.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 6,624 shares of the company’s stock after selling 2,380 shares during the period. Lazard Asset Management LLC’s holdings in Sotera Health were worth $89,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in SHC. Barclays PLC boosted its stake in shares of Sotera Health by 169.8% during the third quarter. Barclays PLC now owns 473,597 shares of the company’s stock valued at $7,909,000 after purchasing an additional 298,085 shares during the period. SG Americas Securities LLC grew its position in shares of Sotera Health by 271.6% in the 4th quarter. SG Americas Securities LLC now owns 36,364 shares of the company’s stock worth $497,000 after buying an additional 26,577 shares during the last quarter. First Citizens Bank & Trust Co. grew its position in shares of Sotera Health by 16.8% in the 4th quarter. First Citizens Bank & Trust Co. now owns 16,689 shares of the company’s stock worth $228,000 after buying an additional 2,402 shares during the last quarter. Blue Trust Inc. increased its stake in shares of Sotera Health by 164.3% during the fourth quarter. Blue Trust Inc. now owns 1,834 shares of the company’s stock valued at $25,000 after buying an additional 1,140 shares during the period. Finally, KBC Group NV boosted its holdings in Sotera Health by 4,094.6% in the fourth quarter. KBC Group NV now owns 186,365 shares of the company’s stock valued at $2,549,000 after acquiring an additional 181,922 shares in the last quarter. Hedge funds and other institutional investors own 91.03% of the company’s stock.

Wall Street Analyst Weigh In

SHC has been the subject of several research reports. Barclays decreased their target price on Sotera Health from $16.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, April 10th. The Goldman Sachs Group raised shares of Sotera Health from a “neutral” rating to a “buy” rating and raised their target price for the company from $14.00 to $17.00 in a research note on Monday, May 5th. Finally, Piper Sandler lowered their target price on shares of Sotera Health from $15.00 to $13.00 and set a “neutral” rating for the company in a report on Wednesday, April 23rd. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $15.80.

Sotera Health Stock Performance

Shares of SHC opened at $12.16 on Monday. The firm has a market capitalization of $3.45 billion, a P/E ratio of 48.64 and a beta of 1.88. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61. Sotera Health has a one year low of $9.53 and a one year high of $17.08. The business has a fifty day moving average of $11.65 and a 200 day moving average of $12.70.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings results on Thursday, May 1st. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.02. The business had revenue of $254.52 million during the quarter, compared to the consensus estimate of $245.56 million. Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.13 EPS. As a group, sell-side analysts anticipate that Sotera Health will post 0.61 EPS for the current year.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.